摘要
目的分析贝那普利和阿托伐他汀联用对2型糖尿病并发肾病的治疗效果。方法选取2020年1月—2021年6月该院收治符合研究条件的76例2型糖尿病并发肾病患者,依据用药不同分为对比组(贝那普利)、研究组(贝那普利+阿托伐他汀),单组例数38,观察评估治疗效果、血糖水平、血脂指标以及肾功能指标等数据差异。结果分析治疗总有效率,研究组(94.74%)较对比组(76.32%)更高,差异有统计学意义(χ^(2)=5.208,P<0.05);测定空腹血糖、餐后2 h血糖以及糖化血红蛋白水平,治疗前,两组比较差异无统计学意义(P>0.05),治疗后,研究组(5.25±1.17)mmol/L、(8.22±1.47)mmol/L、(6.09±1.01)%均较对比组(7.11±1.45)mmol/L、(10.52±1.89)mmol/L、(7.22±1.26)%更低,差异有统计学意义(P<0.05);测定三酰甘油、总胆固醇、低密度及高密度脂蛋白胆固醇,治疗前,两组比较差异无统计学意义(P>0.05),治疗后,研究组(1.42±0.28)、(3.45±0.98)、(3.01±0.42)、(1.82±0.33)mmol/L均较对比组(2.86±0.39)、(5.11±1.03)、(3.57±0.48)、(1.59±0.28)mmol/L更优,差异有统计学意义(P<0.05);测定24 h尿蛋白定量、尿素氮以及血肌酐,治疗前,两组比较差异无统计学意义(P>0.05),治疗后,研究组(0.85±0.31)g、(3.48±0.96)mmol/L、(102.37±8.43)μmol/L均较对比组(1.33±0.38)g、(4.52±1.01)mmol/L、(128.41±10.55)μmol/L更低,差异有统计学意义(P<0.05)。结论在2型糖尿病并发肾病患者临床治疗期间,采用那普利和阿托伐他汀联用方案,治疗总有效率较高,且改善血糖水平、血脂指标以及肾功能指标作用更为明显。
Objective To analyze the therapeutic effect of combination of benazepril and atorvastatin on type 2 diabetes complicated with nephropathy.Methods The samples were taken from January 2020 to June 2021 in the hospital and admitted 76 patients with type 2 diabetes and nephropathy who met the research conditions.Accorded to the different medications,it was divided into a comparison group(benazepril)and a study group(benazepril+atorvastatin),and the number of cases in a single group was 38.Observed and evaluated differences in data such as treatment effects,blood glucose levels,blood lipid indexes,and renal function indexes.Results To analy the total effective rate of treatment,the study group(94.74%)was higher than the control group(76.32%),and the difference was statistically significant(χ^(2)=5.208,P<0.05).The fasting blood glucose,blood glucose 2 h after a meal,and glycosylated hemoglobin levels were measured.Before treatment,there was no statistically significant difference between the two groups(P>0.05).After treatment,the study group(5.25±1.17)mmol/L,(8.22±1.47)mmol/L,(6.09±1.01)%compared with the control group(7.11±1.45)mmol/L,(10.52±1.89)mmol/L,(7.22±1.26)%were lower,the difference was statistically significant(P<0.05).Triglycerides,total cholesterol,low-density and high-density lipoprotein cholesterol were measured.Before treatment,there was no statistically significant difference between the two groups(P>0.05).After treatment,the study group(1.42±0.28)mmol/L,(3.45±0.98)mmol/L,(3.01±0.42)mmol/L,(1.82±0.33)mmol/L compared with the control group(2.86±0.39)mmol/L,(5.11±1.03)mmol/L,(3.57±0.48)mmol/L,(1.59±0.28)mmol/L were better,and the difference was statistically significant(P<0.05).The 24 h urine protein quantification,urea nitrogen and blood creatinine were measured.Before treatment,the difference between the two groups was not statistically significant(P>0.05).After treatment,the study group(0.85±0.31)g,(3.48±0.96)mmol/L,(102.37±8.43)μmol/L compared with the control group(1.33±0.38)g,(4.52±1.01)mmol/L,(128.41±10.55)μmol/L were lower,the difference was statistically significant(P<0.05).Conclusion During the clinical treatment of patients with type 2 diabetes and nephropathy,the combination of napril and atorvastatin has a higher overall effective rate of treatment.And the effect of improving blood glucose level,blood lipid index and renal function index is more obvious.
作者
刘湘湘
LIU Xiangxiang(Department of Pharmacy,Fujian Provincial Hospital,Fuzhou,Fujian Province,350001 China)
出处
《糖尿病新世界》
2021年第24期178-181,共4页
Diabetes New World Magazine
关键词
2型糖尿病
肾病
贝那普利
阿托伐他汀
治疗效果
血糖水平
Type 2 diabetes
Nephropathy
Benazepril
Atorvastatin
Therapeutic effect
Blood glucose level
